Page 198 - Reconstructive Techniques in Musculoskeletal Tumor Surgery

Chapter 9
196
Table 3. Overview of literature on knee replacement in bone tumor surgery.
Study
Number Year of surgery
Implant type*
Follow-up (years)
Site Diagnoses Hinge Fixation (%) (%) type method
Extra- articular resection (%)
Aseptic loosening
Implant survival / cumulative incidence of failure
Pala Myers
247 2003-2010 335 1973-2000
GMRS (Stryker)
4 (2-8)
DF 76; Prim. 98 RH PT 25 Mets. 2
Unc-HA coated 90; cem 9
- Rarely
6%
70 and 58% at 4 and 8 years (survival, all failure modes)
Myers
194 1977-2002
Custom (Stanmore)
Survivors: 14.7 (5-29) Deceased: N/R
PT Prim. 94 FH Mets. 6% RH
49 Cem/ 51 Cem-HA
Rarely
FH: 46% at 10 years; RH 3%
79%, 58%, and 45% at 5, 10, and 15 years, respectively (survival, as a result of aseptic loosening, breakage, infection, etc)
Kinkel Gri n Biau
77 1995-2005 99 1989-2000 91 1972-1994
MUTARS (implantcast)
3.8 (0.3-10.7)
DF 64; Prim. 90 RH PT 36 Mets. 10
Unc 78; cem 22
40 13 3
17 2 20
57% at 5 years (survival, reasons N/R)
Bickels Morgan
110 1990-1998 105 1985-2004
Modular 66%, custom 25%* (Howmedica)
Med. 7.8 (2- 16.5)
DF Prim. 98 FH Non-tum. 2 RH
7 Cem 93
2 -
5 17
93%and88%at5and10 years, respectively, overall survival
Custom (Stanmore)
Survivors: 12 (5-30) Deceased: N/R
DF Prim. 94 FH Mets. 6 RH
48 Unc-HA 52 collar 4; cem-HA
FH: 35% at 10 years; RH: -
83%, 67%, and 51%
at 5, 10, and 15 years, respectively (survival, as a result of aseptic loosening, fracture of the implant, infection, breakage, etc)
KMFTR (Stryker)
Med. 6.1 (0.3- 13.2)
DF 75; Prim. FH PT 25
Unc Cem
N/R for overall population
Custom (Stryker)
Med. 5.2 (0.0- 28.6)
DF 62; Prim. 98 FH PT 38 Mets. 2
76%, 45%, and 29%
at 5, 10, and 15 years, respectively (survival, revision for any reason)
Modular (di erent manufacturers)
Med. 4.8 (0.1- 19.6)
DF 72; N/R RH PT 28
Cem
73%and59%at5and10 years, respectively (survival, failure modes 1–4)
(%) (%)
collar 43; cem 53
collar (N/R)